Novel LXR Modulators with Bicyclic Core for Treating Dyslipidemias
Summary
The USPTO has published a new patent application, US20260083704A1, detailing novel LXR modulators with a bicyclic core for treating dyslipidemias and related metabolic disorders. The application was filed on May 1, 2025, and published on March 26, 2026.
What changed
This document is a publication of a United States patent application (US20260083704A1) filed by inventors associated with the development of novel compounds that act as Liver X Receptor (LXR) modulators. The application specifically describes compounds with a bicyclic core moiety and their potential use in the prophylaxis and/or treatment of dyslipidemias and other metabolic disorders associated with impaired lipid homeostasis.
As this is a patent application publication, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future intellectual property and market exclusivity for specific therapeutic agents. Pharmaceutical and drug manufacturers should monitor patent filings in this area for competitive intelligence and potential licensing opportunities.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
LXR MODULATORS WITH BICYCLIC CORE MOIETY FOR TREATING DYSLIPIDEMIAS
Application US20260083704A1 Kind: A1 Mar 26, 2026
Inventors
Archana VIJAYAKUMAR, Eisuke MURAKAMI, Claus KREMOSER, Jen-Chieh CHUANG, Steve WENG, Ryan Steven HUSS, G. Mani SUBRAMANIAN, Robert P. MYERS
Abstract
The present disclosure relates to novel compounds which are Liver X Receptor (LXR) modulators and to pharmaceutical compositions containing same. The present disclosure further relates to the use of said compounds in the prophylaxis and/or treatment of diseases which are associated with the modulation of LXR, for example, dyslipidemias. The present disclosure further relates to the use of the present compounds in the prophylaxis and/or treatment of metabolic disorders associated with an impairment in lipid homeostasis.
CPC Classifications
A61K 31/404 A61K 31/4155 A61K 31/416 A61K 31/4178 A61K 31/423 A61K 31/4245 A61K 31/427 A61K 31/437 A61K 31/439 A61K 31/4439 A61K 31/454 A61K 31/4709 A61K 31/496 A61K 31/497 A61P 1/16 A61P 3/06
Filing Date
2025-05-01
Application No.
19196617
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.